Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.

ABSTRACT:

Background

Two recently approved bispecific antibodies (bsAbs) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) include epcoritamab (subcutaneous, SC) administered until progression (TTP), and glofitamab (intravenous, IV) for fixed duration (FTD). Understanding patient preferences for treatment attributes is critical for patient-centered decision-making.

Methods

A discrete-choice experiment among 123 DLBCL patients assessed preferences for bsAbs across six attributes: median overall survival (OS, 12- vs 18-months), 24-month complete response (CR) (55% vs 62%), grade 3-4 cytokine release syndrome risk (CRS, 2% vs 5%), CRS-related hospitalization (2% vs 56%), duration (FTD vs TTP) and administration (SC vs IV). Preference weights were estimated using conditional l

SUBMITTER: Mulvey E 

PROVIDER: S-EPMC12622355 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature